Potassium Chloride
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Potassium Chloride: From Potassium Deficiency to Renal Tubular Acidosis
One-Sentence Summary
Potassium chloride is an electrolyte replacement originally used to treat potassium deficiency and constipation. The TxGNN model predicts it may be useful for renal tubular acidosis, but no clinical trials are registered, and the 18 publications retrieved are mostly case reports, small cohorts and older reviews. The prediction mainly reflects supportive correction of low potassium rather than treatment of the underlying disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium deficiency disease; constipation disorder (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium chloride is an electrolyte replacement, its efficacy in potassium deficiency is well established, and mechanistically it may be applicable to the low potassium that accompanies renal tubular acidosis.
Distal renal tubular acidosis commonly causes renal potassium wasting and hypokalaemia, sometimes severe enough to cause periodic paralysis. In the retrieved case reports, patients with severe hypokalaemia were treated with intravenous or oral potassium chloride alongside alkali therapy.
This is correction of a secondary consequence of the disease, not treatment of the underlying tubular defect. The high TxGNN score likely reflects the drug's original potassium-deficiency indication. The prediction should therefore be read as supportive care, not as a new disease-modifying use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The retrieved literature consists of case reports, cohort studies and reviews. No controlled trials were found. The table lists the most relevant publications.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34748193 | 2022 | Case report | Journal of Nephrology | Distal RTA with hypokalaemic periodic paralysis during pregnancy |
| 40288831 | 2025 | Case report | Nefrologia | Primary RTA in pregnancy, with a review of perinatal prognosis |
| 37727491 | 2023 | Case report | World J Clin Cases | Incomplete distal RTA uncovered during pregnancy |
| 38445406 | 2023 | Cohort | La Tunisie Medicale | Genotype-phenotype correlation of distal RTA, including hypokalaemia and nephrocalcinosis |
| 10213645 | 1999 | Cohort | Am J Kidney Dis | Metabolic acidosis in advanced renal failure, diabetic vs non-diabetic patients |
| 786013 | 1976 | Review | Am J Med Sci | Causes, consequences and correction of hypokalaemia |
| 6277192 | 1982 | Review | Am J Med | Review of distal nephron disorders |
| 28509102 | 2015 | Case report | CEN Case Reports | Paediatric Sjögren syndrome with distal RTA |
| 16076719 | 2005 | Case report | Acta Oto-Laryngologica | Distal RTA with large vestibular aqueduct and hearing loss |
| 34595212 | 2021 | Case report | Case Rep Nephrol Dial | Type I RTA with severe hypokalaemia (K 1.6 mEq/L) treated with potassium chloride infusion |
Singapore Market Information
There are 20 valid single-ingredient licences. The following are five main ones, covering the different dosage forms. The data compiled for this report contain no approved indication text for any of them.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07923P | Sterile Potassium Chloride Concentrate Injection 7.45% | Injection | Not stated |
| SIN11566P | Potassium Chloride Injection, Highly Concentrated (400 mEq/l) | Injection | Not stated |
| SIN08437P | Potassium Chloride Mixture 500 mg/5 ml | Solution | Not stated |
| SIN07447P | Potassium Chloride Tablets (Slow-Release) 600 mg | Tablet | Not stated |
| SIN13569P | Potassium Chloride 0.3% w/v and Glucose 5% w/v Intravenous Infusion BP | Infusion, solution | Not stated |
Safety Considerations
- Disease contraindications (from knowledge-graph links, not label text): the main concerns are kidney disease, anuria, heart disease and congestive heart failure, hypertension, peptic ulcer or gastric ulcer, pancreatitis, liver disease, and hypercalcaemia. Other listed conditions include epilepsy, COPD, sarcoidosis, benign prostatic hyperplasia, sickle cell anaemia and Wilson disease.
- Gastrointestinal injury: the retrieved literature repeatedly links solid potassium chloride tablets to upper gastrointestinal mucosal injury and ulceration. Liquid or microencapsulated forms may carry less risk.
- Drug interactions: 100 interactions were identified. Major ones include:
- Potassium-raising or renally active drugs: amiloride, and the angiotensin receptor blockers olmesartan, valsartan and azilsartan.
- ACE inhibitor: benazepril.
- Anticholinergics: atropine, hyoscyamine, homatropine, glycopyrronium, benzatropine and biperiden. These slow gut motility and may worsen mucosal injury from solid potassium forms.
- Antihistamines and tricyclics: chlorpheniramine, acrivastine, brompheniramine, phenyltoloxamine and amitriptyline.
- Moderate interactions include ibuprofen, ketorolac and aliskiren.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The only supporting evidence is case reports, small cohorts and old reviews, and the benefit is limited to correcting secondary hypokalaemia. This is already covered by the existing potassium-deficiency use, so it is not a distinct new indication. The knowledge-graph contraindications, including kidney disease, also overlap with the target population.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are currently missing and block safety screening
- Mechanism of action data
- A clear decision on whether this should be treated as a new indication or as supportive care under the existing potassium-deficiency indication
- Controlled or well-designed observational data on potassium chloride dosing, safety and monitoring in renal tubular acidosis, including serum potassium and renal function monitoring
- Approved indication text for the Singapore licences, to confirm the current labelled scope
Other Predicted Indications (Lower Priority)
All other predictions have evidence level L5 and a Hold recommendation.
- HELIX syndrome, Alstrom syndrome, Pendred syndrome, Senior-Loken syndrome, congenital prothrombin deficiency, NAD(P)HX dehydratase deficiency: no trials or literature were found. A plausible mechanism exists only for HELIX syndrome (electrolyte disturbance), and even that is speculative.
- Dyspepsia, gastroduodenitis, stomach disease: the retrieved literature shows potassium chloride as a cause of gastric and gastrointestinal injury. This is a safety signal against these uses, not supporting evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.